证券代码：600998 证券简称：九州通 公告编号：临 2025-047 九州通医药集团股份有限公司 第六届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 6 月 17 日，九州通医药集团股份有限公司（以下简称"九州通"或 "公司"）召开第六届董事会第十五次会议，本次会议以现场结合通讯的方式召 开，根据公司《董事会议事规则》的相关规定，会议通知已于 2025 年 6 月 9 日 以电话、邮件、微信等方式通知全体董事。本次会议应参加表决董事 14 人，实 际表决董事 14 人，其中公司独立董事汤谷良先生因公务原因，授权委托独立董 事曾湘泉先生代为行使表决权。会议由董事长刘长云先生主持，部分高级管理人 员列席了会议。本次会议的召集和召开程序符合《公司法》及《公司章程》等相 关规定。 经过审议并表决，本次会议通过了以下议案： 二、《关于公司修订 2023-2025 年员工持股计划（草案）及其摘要的议案》 因员工持股计划后续实施的需要，依据 2022 年年度股东大会的授权，公司 拟修订 202 ...

法律意见书 中国·北京 朝阳区建外大街甲 14 号广播大厦 17 层 邮政编码：100022 电话：(010)65219696 传真:(010)88381869 二〇二五年六月 释义 北京海润天睿律师事务所 关于九州通医药集团股份有限公司 修订 2023-2025 年员工持股计划（草案）及第三批分 配的 在本法律意见书中，除非文义另有所指，下列词语具有下述含义： | 九州通、公司 | 指 | 九州通医药集团股份有限公司 | | --- | --- | --- | | 《员工持股计划（草案）》 | 指 | 《九州通医药集团股份有限公司 2023-2025年员工持股 | | | | 计划（草案）》 | | 《员工持股计划（草案修 | 指 | 《九州通医药集团股份有限公司 2023-2026年员工持股 | | 订稿）》 | | 计划（草案）（修订稿）》 | | 本次员工持股计划 | 指 | 九州通医药集团股份有限公司2023-2025年员工持股计 划（本次名称拟修订为九州通医药集团股份有限公司 | | | | 年员工持股计划） 2023-2026 | | 本次修订 | 指 | 九州通医药集团股份有限公司拟修订 20 ...

九州通医药集团股份有限公司 员工持股计划管理办法 第一章 总则 第一条 为规范九州通医药集团股份有限公司（以下简称"九州通"或"公 司"）2023-2026 年员工持股计划（以下简称"本员工持股计划"）的实施，根据 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《关于上市公司实施员工持股计划试点的指导意见》 （以下简称"《指导意见》"）等相关法律、行政法规、规章、规范性文件和《公 司章程》及《九州通医药集团股份有限公司 2023-2026 员工持股计划（草案）》（以 下简称"员工持股计划草案"）之规定，特制定本管理办法。 第二章 员工持股计划的制定 第二条 员工持股计划所遵循的基本原则 （一）依法合规原则 公司实施本员工持股计划，严格按照法律、行政法规的规定履行程序，真实、 准确、完整、及时地实施信息披露。任何人不得利用员工持股计划进行内幕交易、 操纵证券市场等证券欺诈行为。 （二）自愿参与原则 公司实施本员工持股计划遵循公司自主决定、员工自愿参加的原则，公司不 以摊派、强行分配等方式强制员工参加本员工持股计划。 （三）风险自担原则 本员工持股计划参 ...

九州通医药集团股份有限公司 章程 （2025 年 6 月修订） 目 录 1 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东会 第一节 股东 第二节 控股股东和实际控制人 第三节 股东会的一般规定 第四节 股东会的召集 第五节 股东会的提案与通知 第六节 股东会的召开 第七节 股东会的表决和决议 第五章 董事会 第一节 董事的一般规定 第二节 董事会 第三节 独立董事 第四节 董事会专门委员会 第六章 高级管理人员 第七章 财务会计制度、利润分配和审计 第一节 合并、分立、增资和减资 第二节 解散和清算 2 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第八章 通知和公告 第一节 通知 第二节 公告 第九章 合并、分立、增资、减资、解散和清算 第十章 修改章程 第十一章 附则 九州通医药集团股份有限公司章程 第一章 总则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共 和国证券法》（以下简称《证券法》）和其他有关规定 ...

Core Viewpoint - The article discusses the 16th Investor Relations Management Forum held in Yangzhou, where the winners of the Tianma Award for outstanding investor relations management were announced, highlighting the importance of effective communication between listed companies and their investors [1][2]. Group 1: Tianma Award Overview - The Tianma Award, organized by the Securities Times, is one of the earliest evaluation activities focused on investor relations management in China's capital market [2]. - The award aims to enhance the investor relations management level of listed companies and recognize those that excel in this field [2]. Group 2: Award Categories - Six categories of awards were presented: 1. Investor Relations Management Tianma Award 2. Outstanding Secretary of the Board Award 3. Excellent Team Award 4. Shareholder Return Award 5. Innovative Practice Award 6. Hong Kong Stock Market Investor Relations Management Tianma Award [2]. Group 3: Award Winners - A list of companies that received awards includes notable names such as BYD (002594), Mindray Medical (300760), and Yunnan Copper (000878) among others [3][4][5][6][8][9]. - The awards recognize companies across various sectors, indicating a broad commitment to improving investor relations [3][4][5][6][8][9]. Group 4: Notable Individuals - The article also highlights the names of secretaries of the board from awarded companies, showcasing the individuals who play a crucial role in investor relations [8][10]. - This recognition emphasizes the importance of leadership in fostering effective communication with investors [8][10]. Group 5: Hong Kong Stock Market Awards - The article lists the winners of the Hong Kong Stock Market Investor Relations Management Tianma Award, including companies like China Merchants Industry Holdings (1919.HK) and Kuaishou Technology (1024.HK) [19]. - This segment illustrates the growing recognition of investor relations practices in the Hong Kong market [19].

6月12日，"提质增效强信心 稳中求进促发展"——湖北辖区上市公司2025年投资者集体接待日活动暨 2024年度业绩说明会活动在全景路演举办。 图/湖北证监局一级巡视员刘昌华致辞 湖北省上市公司协会秘书长黄玲致辞表示：今天的网上集体接待日活动正是各方增进理解、凝聚共识的 重要契机，希望以此次线上相聚为新的起点，携手并肩、深化互信、凝聚智慧、共谋发展。 图/本次活动开场直播 本次活动是在湖北证监局指导下，湖北省上市公司协会联合深圳市全景网络有限公司举办，活动旨在加 强上市公司投资者沟通交流，引导上市公司做好市值管理工作，推动上市公司持续增强投资者回报，进 一步提升辖区上市公司整体投资价值。 湖北证监局一级巡视员刘昌华致辞指出：希望辖区上市公司要以此次集体接待日活动为契机，与投资者 充分交流，回应关切和诉求，切实履行社会责任。与此同时，希望辖区上市公司要进一步立足自身优 势，聚焦主业、深耕细作，打造核心竞争力，不断通过科技创新提升盈利和可持续发展能力，切实履行 社会责任。 在专业分享环节，TCL环保科技股份有限公司董秘、中国上市公司协会专家顾问讲师田瑞龙就《上市公 司市值管理绩效管理思路》做主题分享。 图/湖北省 ...

Core Viewpoint - The company is implementing a "Three New and Two Transformation" strategy, focusing on new products, new retail, new medical services, digitalization, and real estate securitization to enhance competitiveness and shareholder value [1][5]. New Product Strategy - The company has established a comprehensive new product strategy framework centered around CSO, covering business development, R&D registration, product evaluation, and marketing [1]. - In 2024, the total sales of the CSO brand promotion business reached 19.267 billion yuan, with 2,247 drug and device specifications introduced, including 52 products with sales exceeding 100 million yuan [1]. - The company's pharmaceutical manufacturing and OEM business achieved sales revenue of 3.007 billion yuan, a year-on-year increase of 21.49% [1]. New Retail Strategy - The company is building an integrated online and offline new retail service system, focusing on "ten thousand store franchises" [2]. - The number of franchise pharmacies has exceeded 29,000, generating sales revenue of 5.392 billion yuan, with C-end new retail sales revenue of 2.966 billion yuan [2]. - The logistics network covers over 96% of the country, serving more than 1,900 upstream brand enterprises [2]. New Medical Strategy - The company has developed an efficient clinic operation system and is advancing the "Nine Medical Clinics" membership alliance [2]. - Collaborating with Tencent Cloud, the company has created an AI-assisted diagnostic platform for clinics, enhancing diagnostic efficiency and patient experience [2]. - As of March, the number of member clinics reached 1,377, increasing the company's coverage in clinic channels [2]. Digitalization Strategy - The company has achieved digitalization across various operations, including supply chain management and decision support, and is advancing towards AI integration [3]. - In 2024, R&D investment in digitalization reached 346 million yuan, a year-on-year increase of 24.32% [3]. - The company’s digital platforms have improved operational efficiency and reduced costs, with significant recognition for its digital transformation initiatives [3]. Real Estate Securitization Strategy - The company has established a multi-tiered real estate equity operation platform, including public REITs and Pre-REITs, to attract scarce equity funds [4]. - The public REITs are based on high-quality pharmaceutical warehousing and logistics assets, with a total area of approximately 172,000 square meters recognized as a national intelligent logistics demonstration base [4]. - The company owns over 3 million square meters of pharmaceutical warehousing and logistics assets, with plans for further expansion of REITs listings [4]. Strategic Goals - The strategic objectives of the "Three New and Two Transformation" initiative include enhancing product competitiveness, improving profitability, reaching C-end customers, elevating overall management levels through digitalization, and achieving light asset operations to increase shareholder returns [5].

Summary of Key Points from Conference Call Records Company Overview - **Company**: 九州通 (Jiuzhoutong) - **Industry**: Pharmaceutical and Healthcare Services Core Insights and Arguments 1. **Dividend Distribution**: 九州通 announced a cash dividend of 0.20 yuan per share for the year 2024, with a record date of June 16, 2025, and a payment date of June 17, 2025. The total distribution is based on the total share capital minus shares held in the repurchase account, resulting in a distribution of 2.00 yuan for every 10 shares held [1][2][3]. 2. **Investment in Innovation**: The company established a strategic fund, "Wuhan Jiuying Venture Capital Fund," with a scale of 500 million yuan, focusing on investments in innovative drugs and high-end generics. The fund aims to accelerate the introduction of valuable new products through various collaboration models [3][4]. 3. **Product Development**: 九州通's subsidiary, 湖北九康通生物医药有限公司, is developing an oral antiviral drug for COVID-19, SHEN211, which has been accepted for clinical trial registration. This drug is noted as the first non-peptide 3CL protease inhibitor in China [3]. 4. **Logistics Technology**: The company has developed a comprehensive range of robotic products for logistics operations, including various types of handling robots suitable for different storage conditions. These products are already in use at logistics centers for major clients [4]. 5. **AI and Cloud Collaboration**: 九州通 is collaborating with leading tech companies like Alibaba Cloud and Tencent Cloud to develop AI applications in healthcare, including smart logistics and diagnostic systems. The company is also working on AI-driven solutions for various business scenarios [5]. Additional Important Information 1. **Environmental Initiatives**: The company is advancing its logistics park's photovoltaic project, achieving a total installed capacity of 20.57 MW, generating over 13 million kWh of electricity, and reducing CO2 emissions by approximately 11,021 tons [5]. 2. **Market Position**: 九州通 is recognized as the largest private pharmaceutical commercial enterprise in China and the first to be rated as a 5A logistics enterprise, highlighting its leadership in the industry [2]. 3. **Future Prospects**: The company is actively pursuing opportunities in the fields of innovative drugs, AI applications, and logistics technology, positioning itself for growth in the evolving healthcare landscape [3][5]. Company Overview - **Company**: 冰轮环境 (Binglun Environment) - **Industry**: Environmental Control and Energy Solutions Core Insights and Arguments 1. **Project Wins**: 冰轮环境 announced winning two large cold chain projects with a total bid amount exceeding 190 million yuan, representing about 2.9% of the company's audited revenue for 2024 [6][7]. 2. **Product Offerings**: The company specializes in artificial environment control technologies and energy utilization, with key products including various types of compressors and industrial heat pumps [7]. 3. **Research and Development**: The company is engaged in developing solid oxide batteries and has been involved in projects related to controlled nuclear fusion, emphasizing its role in advanced technology sectors [7]. Additional Important Information 1. **Green Technology**: 冰轮环境's products have been recognized in the national green data center technology product directory, showcasing their application in major data centers across China [8]. 2. **Industry Applications**: The company's cooling solutions have been utilized in significant venues for the Beijing Winter Olympics, demonstrating their capability in high-profile projects [8]. 3. **Strategic Collaborations**: The company is exploring partnerships in the robotics field, particularly in logistics applications, indicating a focus on integrating advanced technologies into their service offerings [9]. Conclusion The conference call records highlight significant developments in both 九州通 and 冰轮环境, showcasing their strategic initiatives in innovation, technology, and market leadership within their respective industries.

换股进展的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 依据募集说明书的相关约定，九州通医药集团股份有限公司（以下简称"公 司"）控股股东楚昌投资集团有限公司（以下简称"楚昌投资"）2022年非公开发 行的可交换公司债券（以下简称"可交债"）持有人于2024年12月19日至2025 年6月9日期间行使换股权利，导致楚昌投资的持股比例被动下降，不触及要约收 购。 证券代码：600998 证券简称：九州通 公告编号：临 2025-044 九州通医药集团股份有限公司 关于控股股东 2022 年非公开发行可交换公司债券 注：本次变动所涉及股份均享有表决权，不存在表决权委托或受限等任何权利限制 或被限制转让的情况。 本次权益变动为可交债持有人依据募集说明书的相关约定行使换股权利所 致，不存在违反《证券法》《上市公司收购管理办法》《上市公司股东减持股份 管理暂行办法》等法律法规和上海证券交易所业务规则等相关规定及相关承诺。 本次可交债换股后，楚昌投资仍为公司控股股东。 二、本次可交债持有人换股前后，控股股 ...

邮政编码：100022 电话：010-65219696 传真：010-88381869 北京海润天睿律师事务所 关于九州通医药集团股份有限公司差异化分红事项的 法律意见书 中国·北京 朝阳区建外大街甲14号广播大厦5层、9层、10层、13层、17层 二〇二五年五月 北京海润天睿律师事务所 关于九州通医药集团股份有限公司差异化分红事项的 法律意见书 致：九州通医药集团股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受九州通医药集团股份有 限公司（以下简称"公司"）委托，根据《中华人民共和国公司法》（以下简称 《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、中国证券 监督管理委员会（以下简称"中国证监会"）发布的《上市公司股份回购规则》 （以下简称《回购规则》）、上海证券交易所发布的《上海证券交易所上市公司 自律监管指引第 7 号——回购股份》（以下简称"《自律指引 7 号》"）等法律、 法规和规范性文件的规定，以及《九州通医药集团股份有限公司章程》（以下简 称《公司章程》）的规定，就公司 2024 年度利润分配涉及的差异化分红特殊除 权除息处理（以下简称"本次差异化分红"）相关事项出具本 ...